Knockdown of DNA methyltransferase-1 inhibits proliferation and derepresses tumor suppressor genes in myeloma cells

Oncology Letters

Volumn 8, Issue 5, 2014, Pages 2130-2134

  Zhou, Wenwen ^a   Chen, Huying ^a   Hong, Xiuli ^a   Niu, Xiaoqing ^a   Lu, Quanyi ^a  

^a XIAMEN UNIVERSITY   (China)

Author keywords

DNA methyltransferases; Myeloma cells; SiRNA; Tumor suppressor gene

Indexed keywords

CHOLECYSTOKININ OCTAPEPTIDE; DNA METHYLTRANSFERASE 1; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; PROTEIN BCL 2; PROTEIN P16; SMALL INTERFERING RNA; SUPPRESSOR OF CYTOKINE SIGNALING 1;

ARTICLE; CELL CYCLE; CELL PROLIFERATION; CONTROLLED STUDY; DNA METHYLATION; DOWN REGULATION; GENE REPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MULTIPLE MYELOMA; POLYMERASE CHAIN REACTION; PROTEIN EXPRESSION; RNA INTERFERENCE; TUMOR SUPPRESSOR GENE; WESTERN BLOTTING;

EID: 84907144050     PISSN: 17921074     EISSN: 17921082     Source Type: Journal    
DOI: 10.3892/ol.2014.2481     Document Type: Article

References (35)

1. Benjamin M, Reddy S and Brawley OW: Myeloma and race: a review of the literature. Cancer Metastasis Rev 22: 87-93, 2003.
2. Siegel R, Ward E, Brawley O, et al: Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths. CA Cancer J Clin 61: 212-236, 2011.
3. Richardson PG, Barlogie B, Berenson J, et al: Clinical factors predictive of outcome with bortezomib in patients with relapsed, refractory multiple myeloma. Blood 106: 2977-2981, 2005.
4. Richardson PG, Weller E, Lonial S, et al: Lenalidomide, bortezomib, and dexamethasone combination therapy in patients with newly diagnosed multiple myeloma. Blood 116: 679-686, 2010.
5. Chen T and Li E: Structure and function of eukaryotic DNA methyltransferases. Curr Top Dev Biol 60: 55-89, 2004.
6. Robertson KD: DNA methylation and human disease. Nat Rev Genet 6: 597-610, 2005.
7. Belinsky SA, Nikula KJ, Baylin SB, et al: A microassay for measuring cytosine DNA methyltransferase activity during tumor progression. Toxicol Lett 82-83: 335-340, 1995.
8. Vertino PM, Yen RW, Gao J and Baylin SB: De novo methylation of CpG island sequences in human fibroblasts overexpressing DNA (cytosine-5-)-methyltransferase. Mol Cell Biol 16: 4555-4565, 1996.
9. Ng MH, Chung YF, Lo KW, et al: Frequent hypermethylation of p16 and p15 genes in multiple myeloma. Blood 89: 2500-2506, 1997.
10. Mateos MV, García-Sanz R, Lopez-Perez R, et al: Methylation is an inactivating mechanism of the p16 gene in multiple myeloma associated with high plasma cell proliferation and short survival. Br J Haematol 118: 1034-1040, 2002.
11. Chim CS, Liang R, Fung TK, et al: Epigenetic dysregulation of the death-associated protein kinase/p14/HDM2/p53/Apaf-1 apoptosis pathway in multiple myeloma. J Clin Pathol 60: 664-669, 2007.
12. Ng MH, Lau KM, Wong WS, et al: Alterations of RAS signalling in Chinese multiple myeloma patients: absent BRAF and rare RAS mutations, but frequent inactivation of RASSF1A by transcriptional silencing or expression of a non-functional variant transcript. Br J Haematol 123: 637-645, 2003.
13. Galm O, Yoshikawa H, Esteller M, et al: SOCS-1, a negative regulator of cytokine signaling, is frequently silenced by methylation in multiple myeloma. Blood 101: 2784-2788, 2003.
14. Galm O, Wilop S, Reichelt J, et al: DNA methylation changes in multiple myeloma. Leukemia 18: 1687-1692, 2004.
15. Baylin SB and Ohm JE: Epigenetic gene silencing in cancer - a mechanism for early oncogenic pathway addiction? Nat Rev Cancer 6: 107-116, 2006.
16. Bestor TH: The DNA methyltransferases of mammals. Hum Mol Genet 9: 2395-2402, 2000.
17. Szyf M, Pakneshan P and Rabbani SA: DNA methylation and breast cancer. Biochem Pharmacol 68: 1187-1197, 2004.
18. Xu M, Gao J, Du YQ, et al: Reduction of pancreatic cancer cell viability and induction of apoptosis mediated by siRNA targeting DNMT1 through suppression of total DNA methyltransferase activity. Mol Med Rep 3: 699-704, 2010.
19. Milutinovic S, Knox JD and Szyf M: DNA methyltransferase inhibition induces the transcription of the tumor suppressor p21 (WAF1/CIP1/sdi1). J Biol Chem 275: 6353-6359, 2000.
20. Ghoshal K and Bai S: DNA methyltransferases as targets for cancer therapy. Drugs Today (Barc) 43: 395-422, 2007.
21. Auerkari EI: Methylation of tumor suppressor genes p16(INK4a), p27(Kip1) and E-cadherin in carcinogenesis. Oral Oncol 42: 5-13, 2006.
22. Chim CS, Fung TK and Liang R: Disruption of INK4/CDK/Rb cell cycle pathway by gene hypermethylation in multiple myeloma and MGUS. Leukemia 17: 2533-2535, 2003.
23. Komazaki T, Nagai H, Emi M, et al: Hypermethylation-associated inactivation of the SOCS-1 gene, a JAK/STAT inhibitor, in human pancreatic cancers. Jpn J Clin Oncol 34: 191-194, 2004.
24. Jost E, Gezer D, Wilop S, et al: Epigenetic dysregulation of secreted Frizzled-related proteins in multiple myeloma. Cancer Lett 281: 24-31, 2009.
25. Tshuikina M, Jernberg-Wiklund H, Nilsson K, et al: Epigenetic silencing of the interferon regulatory factor ICSBP/IRF8 in human multiple myeloma. Exp Hematol 36: 24-31, 2008.
26. Lin RK, Hsu HS, Chang JW, et al: Alteration of DNA methyltransferases contributes to 5'CpG methylation and poor prognosis in lung cancer. Lung Cancer 55: 205-213, 2007.
27. Ahluwalia A, Hurteau JA, Bigsby RM, et al: DNA methylation in ovarian cancer. II. Expression of DNA methyltransferases in ovarian cancer cell lines and normal ovarian epithelial cells. Gynecol Oncol 82: 299-304, 2001.
28. Robert MF, Morin S, Beaulieu N, et al: DNMT1 is required to maintain CpG methylation and aberrant gene silencing in human cancer cells. Nat Genet 33: 61-65, 2003.
29. Ting AH, Schuebel KE, Herman JG, et al: Short double-stranded RNA induces transcriptional gene silencing in human cancer cells in the absence of DNA methylation. Nat Genet 37: 906-910, 2005.
30. Giuliani N, Colla S, Sala R, et al: Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. Blood 100: 4615-4621, 2002.
31. Xiao W, Hodge DR, Wang L, et al: NF-kappaB activates IL-6 expression through cooperation with c-Jun and IL6-AP1 site, but is independent of its IL6-NFkappaB regulatory site in autocrine human multiple myeloma cells. Cancer Biol Ther 3: 1007-1017, 2004.
32. Conticello C, Giuffrida R, Adamo L, et al: NF-κB localization in multiple myeloma plasma cells and mesenchymal cells. Leuk Res 35: 52-60, 2004.
33. Kannaiyan R, Hay HS, Rajendran P, et al: Celastrol inhibits proliferation and induces chemosensitization through down-regulation of NF-κB and STAT3 regulated gene products in multiple myeloma cells. Br J Pharmacol 164: 1506-1521, 2011.
34. Baliga BC and Kumar S: Role of Bcl-2 family of proteins in malignancy. Hematol Oncol 20: 63-74, 2002.
35. Chen Q, Ray S, Hussein MA, et al: Role of Apo2L/TRAIL and Bcl-2-family proteins in apoptosis of multiple myeloma. Leuk Lymphoma 44: 1209-1214, 2003